drugset
drugset / Trial / NCT00379860

Study Evaluation LXR-623 in Healthy Adults

NCT00379860 ↗

Phase 1 Terminated Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedSingle-groupDouble-blindTreatment

Summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Timeline

Start
2006-10
Primary completion
—
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LXR-623 Small molecule — Oral

Indications

No indication recorded.